Genetic Polymorphisms, LDL-C and sdLDL-C Help Optimize Coronary Heart Disease (CHD) Therapy

Ruozhu Dai
Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University

Huilin Zhuo
Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University

Wei Wang
Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University

Xinjun Wang (✉ xjwang16@fudan.edu.cn)
Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai

Xiaoyu Zhao
State Key Laboratory of Genetic Engineerings, School of Life Sciences, Fudan University

Research Article

Keywords: Genetic polymorphisms, LDL-C, sdLDL-C, coronary heart disease, precision medicine

DOI: https://doi.org/10.21203/rs.3.rs-140205/v1

License: ☺️ 🍀 This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Low-density lipoprotein cholesterol (LDL-C) and small, dense LDL-C (sdLDL-C) are important risk indicators of coronary heart disease (CHD), but their application in therapy monitoring of CHD is still far from being elucidated. Following the concept of precision medicine, we investigated whether the scientific medication based on medication-sensitive genes can reverse the LDL-C and sdLDL-C status in human bloodstream, so as to reveal the possibility of them as a monitoring indicator of CHD efficacy.

Methods: A prospective study of CHD cohort containing 208 Chinese CHD patients (158 males and 50 females) and 20 healthy people (14 males and 6 females) was recruited. LDL-C and its subfractions were detected before and after treatment. Polymorphism of medication-sensitive genes, including SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were detected for medication guidance.

Results: Nearly half of Chinese CHD patients (47.60%, 99/208) had genetic polymorphisms with homozygous or heterozygous mutations within these three genes. LDL-1 and LDL-2, subfractions of LDL-C, had a 100% positive rate in CHD patients and healthy people. However, sdLDL-C components of LDL-5 to LDL-7 were only enrichment in CHD patients. Moreover, the mean amount of sdLDL-C subfractions in CHD patients was significantly higher than that in healthy people. Among 180 patients with treatment remission, 81.67% (n=147) of CHD patients had decreased LDL-C, while 61.67% (n=111) of patients had decreased sdLDL-C.

Conclusion: sdLDL-C has better accuracy on CHD screening than LDL-C, while LDL-C was more suitable for CHD therapy monitoring. Combined medication-sensitive genes polymorphism, LDL-C and sdLDL-C detection would optimize the treatment strategy for CHD patients.

Introduction

Coronary heart disease (CHD) is an important public health disease that causes death and disability [1]. Based on the data from the National Health and Nutrition Examination Survey (NHANES) 2011 to 2014, an estimated 16.5 million Americans ≥ 20 years of age had CHD, and approximately 720,000 new coronary events occurred in America in 2018 [1]. In China, more than 10 million people have been affected by this disease [2]. Low-density lipoprotein cholesterol (LDL-C) plays a pivotal role in the progression of CHD, as verified by genetic, pathology, observational, and intervention studies [3-6]. In 36,375 participants and a low 10-year risk cohort with long-term follow-up, LDL-C and non-HDL-C ≥160 mg/dL were independently associated with a 50% to 80% increased relative risk of cardiovascular disease (CVD) mortality [7]. The risk of CHD is accelerated by 10 to 20 years in men and 20 to 30 years in women with LDL-C levels ≥190 mg/dL [8], and the Adult Treatment Panel (ATP III) cholesterol guideline from 2001 [9] and the 2013 American College of Cardiology (ACC)\American Heart Association (AHA) guideline [10] recommend intensive treatment of patients with primary elevation of LDL-C [8,11]. CHD treatment may include reducing the level of LDL-C to prevent recurrent cardiovascular events (CEs) [5],...
and LDL-C has now largely replaced total cholesterol as a risk marker and the primary treatment target for hyperlipidemia [12].

LDL-C is a heterogeneous class of particles, and accumulating evidence suggests that different LDL subfractions vary in their risk profiles [13, 14]. Lipoprotein profiles consisting of primarily LDL-1 and LDL-2 subfractions have been designated as Pattern A, while profiles with predominantly small and dense subfractions (LDL-3 to LDL-7), known as small, dense LDLs (sdLDLs), have been designated as Pattern B [15]. Patients with the same LDL-C levels may have different cardiovascular risks, due to the difference on sdLDL-C subfractions [16-18]. In 808 participants from the Chinese Multiprovincial Cohort Study, sdLDL-C was independently associated with the progression of carotid atherosclerosis [19]. The study showed that sdLDL-C was the most effective predictor of residual risk of future CEs in those using statins and in high-risk coronary artery disease patients with diabetes or hypertriglyceridemia [20].

Although there are many reports about the excellent predictive performance of LDL-C and sdLDL-C for cardiovascular disease, the clinical application research especially in drug curative evaluation is still lacking; therefore, we wanted to assess patient status by LDL-C or sdLDL-C concentration change before and after using clopidogrel or statins to obtain more clinical application value, especially in Chinese CHD patients. A total of 208 CHD patients from the Quanzhou First Hospital Affiliated to Fujian Medical University (Fujian, China) were enrolled. CHD patients were assessed for LDL-C and sdLDL-C before and after treatment with statins or clopidogrel until the disease was alleviated.

To improve the treatment effect, genetic testing before medication administration was recommended to patients [21-23]. Simvastatin is the most common prescription medication for cholesterol reduction, but a single nucleotide polymorphism (SNP), rs4149056 T>C, in SLC01B1 increases systemic exposure to simvastatin and the risk of muscle toxicity [21]. Individuals carrying the CYP2C19*2 allele have impaired pharmacodynamic responses to clopidogrel [22]. CYP2C19*2 and CYP2C19*3 can be genetically screened, and appropriate dose adjustments can be made on the basis of a patient’s CYP2C19 genotype [23]. Therefore, we intended to perform pretreatment screening of SLC01B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) with an Agena Bioscience MassARRAY system, which is an advanced detection system based on MALDI-TOF MS technology, with superfunction to detect dozens of gene loci in one sample [24]. Finally, the polymorphisms of these three genes were analyzed to help implement more effective treatment, and LDL-C and sdLDL-C data before and after treatment were analyzed. Overall, the clinical values of multigene testing, LDL-C or sdLDL-C were evaluated to acquire the best therapeutic effect for CHD patients. The flow chart is shown in Figure 1A.

**Materials And Methods**

**Patients and sample collection**
Subjects were enrolled from the Quanzhou First Hospital Affiliated to Fujian Medical University (Fujian, China) from Jan 2018 to May 2020. There were a total of 228 subjects, including 208 CHD patients (158 males and 50 females) with a mean age of 64.48 and 20 healthy people (14 males and 6 females) with a mean age of 45.05 (Table 1). Peripheral blood samples (0.5 mL each) were extracted from subjects and centrifuged at 800 × g for 10 minutes to obtain supernatant plasma samples (0.2 mL each) for LDL-C detection and peripheral blood cell sediment for MassARRAY SNP detection. Under the guidance of the results of SNP, all CHD patients were given precise medication (mainly statins) according to the dosage recommended in Technical Guidelines for Gene Detection of Drug Metabolic Enzymes and Drug Targets (2015, China).

**LDL-C, sdLDL-C and SNP detection**

The detection of LDL-C, sdLDL-C and medication-sensitive genes, including SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were performed by a third-party medical diagnostics company with clinical laboratory qualification. The technique details were listed in Supplementary Materials.

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism 5 statistical software (GraphPad Software, Inc., San Diego, CA, USA). P<0.05 indicated a statistically significant difference.

**Results**

**Multitudinous gene polymorphisms associated with drug efficacy in Chinese CHD patients.**

Statins, clopidogrel and other drugs were used for CHD treatment in the clinic. To ensure good therapeutic effects, genetic testing was recommended for patients before remedy with statins or clopidogrel [21-23]. In previous studies, SLCO1B1 (rs4149056, 521T>C) increased systemic exposure to simvastatin and had a risk of muscle toxicity, CYP2C19*2 and CYP2C19*3 could affect appropriate drug dose adjustment [21, 23], and gene loci SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were detected in this study by MassARRAY before treatment.

After testing, 47.60% (99/208) of patients had genetic polymorphisms of homozygous or heterozygous mutations; in specific, SLCO1B1 (521T>C) TT, TC, and CC were identified in 80.29%, 19.23%, and 0.48% of patients, respectively; CYP2C19*2 (681G>A) GG, GA, and AA were identified in 60.10%, 34.13%, and 5.77% of patients, respectively, while CYP2C19*3 (636G>A) GG, GA, and AA were identified in 92.31%, 7.69%, and 0.00% of patients, respectively (Figure 1B). The results showed that these three genes had multitudinous
polymorphisms in Chinese CHD patients and further affirmed the significance of polymorphism detection before statin or clopidogrel therapy.

**CHD patients had higher expression and more types of sdLDL-C subfractions.**

For subfractions of LDL-C and sdLDL-C that were related to CVD [16-18], the precise subfraction expression levels of LDL-C and sdLDL-C in CHD patients and healthy people were detected using a Quantimetrix Lipoprint system. After analysis, the typical lipoprotein subfraction images showed that LDL-1 and LDL-2, known as Pattern A, collectively existed in the plasma of healthy people and CHD patients (Figure 2A), while CHD patients had extra LDL-3 to LDL-7, known as Pattern B or sdLDL-C (Figure 2B). To ensure robust results, samples from 228 subjects were analyzed, including 208 CHD patients and 20 healthy people (Table 1).

The results revealed that the detection rates of LDL-1 to LDL-7 subfractions in CHD patients were 100%, 100%, 99.04%, 94.71%, 62.98%, 18.75%, and 4.33%, respectively, while those in healthy people were 100%, 100%, 95%, 25%, 0%, 0%, and 0%, respectively (Figure 2C). Pattern A had a 100% detection rate in CHD patients and healthy people, while sdLDL-C subfractions were more abundant in CHD patients than in healthy people (Figure 2C). This result was also consistent with previous studies, and sdLDL-C was a high risk factor for CHD [17]. Then, the mean amounts of subfractions were calculated; LDL-1 to LDL-7 in CHD patients were 28.26 mg/dL, 31.47 mg/dL, 18.14 mg/dL, 9.13 mg/dL, 2.74 mg/dL, 0.49 mg/dL, and 0.28 mg/dL, while these subfractions in healthy people were 45.05 mg/dL, 23.70 mg/dL, 31.15 mg/dL, 22.8 mg/dL, 5.7 mg/dL, 0.35 mg/dL, 0 mg/dL, 0 mg/dL, and 0 mg/dL, respectively (Figure 2D and Table 1). CHD patients had higher expression of sdLDL-C subfractions than healthy people.
|                      | CHD patients (Mean ± SD) | Healthy people (Mean ± SD) |
|----------------------|--------------------------|---------------------------|
|                      | Male     | Female  | All    | Male     | Female  | All    |
|                      | n = 158  | n = 50  | n = 208 | n = 14   | n = 6   | n = 20 |
| Age (year)           |          |         |        |          |         |        |
|                      | 62.46 ± 12.08 | 70.86 ± 7.90 | 64.48 ± 11.76 | 45.57 ± 9.50 | 43.83 ± 6.27 | 45.05 ± 8.53 |
| Body mass index (kg/m²) | 24.06 ± 2.89 | 24.53 ± 2.99 | 24.17 ± 2.91 | 24.17 ± 1.97 | 22.60 ± 2.77 | 23.70 ± 2.29 |
| LDL-1 mg/dl          |          |         |        |          |         |        |
|                      | 28.06 ± 14.91 | 28.88 ± 15.68 | 28.26 ± 15.06 | 31.0 ± 14.33 | 31.5 ± 12.57 | 31.15 ± 13.50 |
| LDL-2 mg/dl          |          |         |        |          |         |        |
|                      | 31.85 ± 14.15 | 30.26 ± 13.05 | 31.47 ± 13.88 | 23.0 ± 7.42 | 22.33 ± 6.41 | 22.8 ± 6.97 |
| LDL-3 mg/dl          |          |         |        |          |         |        |
|                      | 17.94 ± 9.60 | 18.76 ± 10.92 | 18.14 ± 9.92 | 5.64 ± 3.05 | 5.83 ± 2.04 | 5.7 ± 2.74 |
| LDL-4 mg/dl          |          |         |        |          |         |        |
|                      | 8.92 ± 7.78 | 9.78 ± 9.10 | 9.13 ± 8.10 | 0.5 ± 0.76 | 0 | 0.35 ± 0.67 |
| LDL-5 mg/dl          |          |         |        |          |         |        |
|                      | 2.86 ± 4.15 | 2.34 ± 3.18 | 2.74 ± 3.94 | 0 | 0 | 0 |
| LDL-6 mg/dl          |          |         |        |          |         |        |
|                      | 0.59 ± 2.35 | 0.18 ± 0.48 | 0.49 ± 2.07 | 0 | 0 | 0 |
| LDL-7 mg/dl          |          |         |        |          |         |        |
|                      | 0.35 ± 2.52 | 0.06 ± 0.42 | 0.28 ± 2.21 | 0 | 0 | 0 |
| Total cholesterol (mmol/l) |          |         |        |          |         |        |
|                      | 5.02 ± 1.53 | 5.47 ± 1.72 | 5.13 ± 1.59 | 3.85 ± 0.71 | 3.97 ± 0.69 | 3.88 ± 0.69 |
| Total triglycerides (mmol/l) |          |         |        |          |         |        |
|                      | 1.45 ± 0.94 | 1.63 ± 0.93 | 1.50 ± 0.94 | 1.27 ± 0.85 | 1.09 ± 0.31 | 1.21 ± 0.72 |
| Plasma HDL-C (mmol/l) |          |         |        |          |         |        |
|                      | 1.09 ± 0.46 | 1.19 ± 0.24 | 1.11 ± 0.42 | 1.35 ± 0.25 | 1.40 ± 0.08 | 1.36 ± 0.21 |
| Plasma LDL-C (mmol/l) |          |         |        |          |         |        |
|                      | 3.21 ± 1.28 | 3.51 ± 1.50 | 3.28 ± 1.34 | 2.26 ± 0.68 | 2.31 ± 0.63 | 2.28 ± 0.65 |
| Apo A1 (g/l)         |          |         |        |          |         |        |
|                      | 1.25 ± 0.25 | 1.34 ± 0.21 | 1.27 ± 0.24 | 1.28 ± 0.08 | 1.25 ± 0.10 | 1.27 ± 0.09 |
| Apo B (g/l)          |          |         |        |          |         |        |
|                      | 1.04 ± 0.33 | 1.13 ± 0.37 | 1.06 ± 0.34 | 0.69 ± 0.16 | 0.81 ± 0.24 | 0.73 ± 0.19 |
LDL-C had better properties for CHD monitoring.

The clinical effect of LDL-C and sdLDL-C was then studied on CHD patient monitoring. A total of 208 CHD patients (158 males and 50 females) were enrolled, and their disease was alleviated after treatment. In total, 169 patients (81.25%) and 126 patients (60.58%) exhibited LDL-C and sdLDL-C decreases (Figure 3A). All 208 CHD patients were evaluated for LDL-C and sdLDL-C before treatment; after treatment and disease remission, 180 CHD patients (134 males and 46 females) underwent detection once, and the percentage of patients with an LDL-C decrease was 81.67% (n=147), while the percentage of patients with an sdLDL-C decrease was 61.67% (n=111) (Figure 3A). Twenty patients (17 males and 3 females) underwent posttreatment detection twice; the percentages with LDL-C and sdLDL-C decreases were 80.00% (n=16) and 55.00% (n=11), respectively (Figure 3A).

To observe the dynamic changes of LDL-C and sdLDL-C in the process of disease remission, 8 CHD patients (7 males and 1 female) who underwent detection four times (one time before treatment and three times after treatment) were analyzed (Figure 3B). As shown in from Figure 3A, the percentages of patients with LDL-C and sdLDL-C decreases were 75.00% (n=6) and 50.00% (n=4), respectively. However, the expression changes of LDL-C and sdLDL-C in the same patient were not exactly the same. For instance, the expression levels of LDL-C and sdLDL-C in patient 6 were both significantly decreased and remained relatively stable, with low expression in follow-up monitoring, while patient 5 had low expression sdLDL-C after therapy but had higher expression of LDL-C, though anesis of the CHD occurred after treatment (Figure 3C). Overall, the expression of LDL-C was more consistent with the disease course of the patient than sdLDL-C.

LDL-C had a better monitoring effect than other clinical biomarkers.

To better understand the monitoring utility of LDL-C and sdLDL-C in CHD patients, they were compared with other clinical biomarkers, such as total cholesterol, total triglycerides, plasma HDL-C, plasma LDL-C, Apo A1, and Apo B. Forty-seven CHD patients were chosen from the 208 patients, and all of these biomarkers were detected before and after treatment. When CHD anesis occurred, the expression levels of total cholesterol, total triglycerides, plasma LDL-C, Apo A1, Apo B, LDL-C and sdLDL-C were decreased, and plasma HDL-C was possibly increased.

Among the 47 CHD patients (39 males and 8 females), the percentages of those with decreased total cholesterol, total triglycerides, plasma LDL-C, Apo A1, Apo B, LDL-C, and sdLDL-C and increased plasma HDL-C were 82.98%, 40.43%, 80.85%, 53.19%, 65.96%, 76.60%, 65.96%, and 25.53%, respectively (Figure 3D). Although 82.98% of the CHD patients had decreased total cholesterol, total cholesterol is composed of LDL-C and HDL-C and thus was not clinically significant (Figure 3D). LDL-C was a better biomarker for CHD treatment monitoring than sdLDL-C and other clinical biomarkers.
Conclusion. sdLDL-C was more suitable for CHD screening than LDL-C, while LDL-C was more suitable for CHD monitoring than sdLDL-C. Combined medication-related gene polymorphism, LDL-C and sdLDL-C detection would better optimize the treatment strategy for Chinese CHD patients.

Discussion

Statins are currently effective in the treatment of CHD and lowering blood lipids [26], and clopidogrel has been recommended to treat CHD in current clinical practice guidelines [27]. Before use, SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were detected to ensure the best treatment was administered [21-23]. In this study, the SNPs of these genes were detected by a Agena Bioscience MassARRAY system, which had the advantages of detecting dozens of gene loci in one sample [24], requiring fewer samples, having a lower cost, and obtaining results in a shorter time than the Sanger sequencing method [28]. The results showed that there were three genotypes associated with SLCO1B1 (521TT, 521TC, 521CC), CYP2C19*2 (681GG, 681GA, 681AA) and two genotypes associated with CYP2C19*3 (636GG, 636GA) in these 208 CHD patients (Figure 1B). A total of 47.60% patients had homozygous or heterozygous mutations (Figure 2C), and polymorphisms detection before statin or clopidogrel therapy could lead to better treatment strategies for Chinese CHD patients.

Numerous studies have shown that LDL-C and sdLDL-C were related to CEs [18, 20]. LDL-C subfractions were detected prior to treatment in CHD patients and healthy people, and we identified the presence of LDL-5 C, LDL-6 C, and LDL-7 C in CHD patients, but not in healthy people (Figure 2C and Figure 2D, Table 1). The mean amounts of sdLDL-C subfractions were calculated; CHD patients also had higher expression of sdLDL-C subfractions than healthy people (Figure 2D). These results suggested that sdLDL-C (LDL-3 C to LDL-7 C) was a high-risk factor for CHD; thus, sdLDL-C detection had greater clinical significance in CHD screening. Our results were consistent with previous studies [16-18].

Conclusions

In the meantime, the monitoring effect of LDL-C and sdLDL-C was affirmed; after treatment and remission, CHD patients with LDL-C and sdLDL-C decreases attained 81.25% and 60.58% (Figure 3A). Although the change curves of LDL-C and sdLDL-C expression were not necessarily consistent in one patient (Figure 3C), in general, the coincidence rate of LDL-C in the disease state was greater than that of sdLDL-C. Other clinical biomarkers, total cholesterol, total triglycerides, plasma HDL-C, plasma LDL-C, Apo A1, and Apo B versus LDL-C and sdLDL-C, and ultimately LDL-C were also better biomarkers for CHD treatment monitoring (Figure 3D).

Declarations

Acknowledgements:
Zheng Wang and Ya Liu from Shanghai Biotecan Pharmaceuticals Co., Ltd are acknowledged for their assistance in the development of lipoprotein detection method. Hayley Zhuoping Xu, Xianshui Zhang, Xiaojie Jiang and Juan Liu from Biotecan Medical Diagnostics Co., Ltd. are acknowledged for their assistance in the LDL-C and sdLDL-C detection.

Authors’ contributions:

Ruozhu Dai, Xinjun Wang and Xiaoyu Zhao contributed to the study conception and experimental design. Huilin Zhuo contributed to the clinical sample collection, sampled detection and data analysis. Xiaoyu Zhao, Xinjun Wang and Wei Wang contributed to data analysis, manuscript writing and revision. All authors critically revised the manuscript, gave final approval and agreed to be accountable for all aspects of the work, ensuring its integrity and accuracy.

Funding:

This work was supported by the Natural Science Foundation of Fujian Province (No: 2018J01202) and scientific instruments application methods project of Shanghai Science and technology innovation action plan (NO:19142200800).

Availability of data and materials:

All data generated or analysed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate:

All experimental protocols in this study was approved by the ethics committee of Quanzhou First Hospital Affiliated with Fujian Medical University. All patients provided written informed consent for this study. All methods in this study carried out in accordance with the Declaration of Helsinki.

Consent for publication:

Informed consent was obtained from all participants for publication.

Conflicting Interests:

The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Authors’ information:

1Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University, China.
2Shanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai Zhangjiang Institute of Medical Innovation, China. 3State Key Laboratory of Genetic Engineerings, School of Life Sciences, Fudan University, China.
4Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China. Wei Wang, Xinjun Wang and Xiaoyu Zhao are co-corresponding authors of this article.

References

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R et al: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018, 137(12):e67-e492.
2. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, Wu ZS, Li HJ, Gu DF, Yang YJ et al: China cardiovascular diseases report 2015: a summary. Journal of geriatric cardiology : JGC 2017, 14(1):1-10.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
4. Catapano AL, Ference BA: IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. Atherosclerosis 2015, 241(2):498-501.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
6. Chamberlain AM, Cohen SS, Weston SA, Fox KM, Xiang P, Killian JM, Qian Y: Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease. The American journal of cardiology 2019, 123(11):1739-1744.
7. Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM et al: Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation 2018, 138(21):2315-2325.
8. Perak AM, Ning H, de Ferranti SD, Gooding HC, Wilkins JT, Lloyd-Jones DM: Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation 2016, 134(1):9-19.
9. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001, 285(19):2486-2497.

10. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014, 63(25 Pt B):2889-2934.

11. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG et al: Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology 2016, 67(22):2578-2589.

12. Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM: A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of clinical lipidology 2016, 10(3):472-489.

13. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P et al: ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(1):3-46.

14. Packard CJ: Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Current opinion in lipidology 2006, 17(4):412-417.

15. Austin MA, Hokanson JE, Brunzell JD: Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Current opinion in lipidology 1994, 5(6):395-403.

16. Blake GJ, Otvos JD, Rifai N, Ridker PM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002, 106(15):1930-1937.

17. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. Jama 1996, 276(11):875-881.

18. Krychiuk KA, Kastl SP, Pfaffenberger S, Lenz M, Hofbauer SL, Wonnerth A, Koller L, Katsaros KM, Pongratz T, Goliash G et al: Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. PloS one 2015, 10(4):e0123367.

19. Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, Liu J, Deng Q, Zhao D: High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study. Journal of atherosclerosis and thrombosis 2019.

20. Sakai K, Koba S, Nakamura Y, Yokota Y, Tsunoda F, Shoji M, Itoh Y, Hamazaki Y, Kobayashi Y: Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease. Geriatrics & gerontology international 2018, 18(6):965-972.
21. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM et al: The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clinical pharmacology and therapeutics 2014, 96(4):423-428.

22. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR et al: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical pharmacology and therapeutics 2013, 94(3):317-323.

23. Hassani Idrissi H, Hmimech W, Khorb NE, Akoudad H, Habbal R, Nadifi S: A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. BMC research notes 2018, 11(1):46.

24. Min KW, Kim WS, Jang SJ, Choi YD, Chang S, Jung SH, Kim L, Roh MS, Lee CS, Shim JW et al: MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study. Journal of cancer research and clinical oncology 2016, 142(10):2209-2216.

25. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clinical chemistry 2001, 47(2):266-274.

26. Lu Y, Cheng Z, Zhao Y, Chang X, Chan C, Bai Y, Cheng N: Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis 2016, 254:215-227.

27. Guo MZ, Wang TY, Yang J, Chang H, Ji S, Tang DQ: Interaction of clopidogrel and fufang danshen dripping pills assay in coronary heart disease based on non-target metabolomics. Journal of ethnopharmacology 2019, 234:189-196.

28. Liu J, Xu Z, Li Y, Dai S, Liu J, Pan J, Jiang Y: Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping. Molecular membrane biology 2019, 35(1):1-8.